Professor Michael Boyer

AM
Clinical Professor
Medicine, Central Clinical School

Telephone +61 2 8514 0922
Fax +61 2 95157404

Website Related website

Map

International links

Singapore

(Cancer Therapeutics Research Group) Director of CTRG

Selected grants

2014

  • NITRO Trial: A randomised phase III trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer; Davidson A, Boyer M, Millward M, Mitchell P, McLachlan S, Hughes B; National Health and Medical Research Council (NHMRC)/Project Grants.

2013

  • QX100 Droplet Digital PCR system for Shared Used at the Open Access, Multi-User Molecular Biology Core Facility; Richardson D, Kril J, Murphy C, Vandenberg R, Rendina L, Dos Remedios C, Ju Y, Kovacevic Z, Lyons G, Sutherland G, Lay P, Ammit A, Lai D, Morris B, Day M, Dong Q, Bao B, Huang M, Camp A, Boyer M, Whittington R, Byrne M, Hanrahan J, Fu D, Jansson P, Lane D, Bagley E, Hibbs D, Zhang D, Fraser S, Scolyer R, Black J, Halliday G, Christie M, Zreiqat H, Murray M, Slobedman B, Naylor M, Burgess J, Triccas J, Mason R, Chadban S, Combes V, Lovicu F, McLennan S, Kalinowski D, Sharland A, Johnstone D, Groundwater P, Dixon K, Zhou F, Lovejoy D, Lu Z, Zhu L, Goldsbury C, Witting P, Buckland M, Assinder S, Purdie (Williams) A, Codd R, Owens T, Hambly B; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Robotic High Throughput Western Analysis for the Open Access, Multi-User Sydney Cancer Research Core Facility; Richardson D, Scolyer R, Boyer M, Halliday G, Damian D, Christopherson R, Joshua D, Kench J, Hong A, Murray M, Lee C, Kalinowski D, Naylor M, Lay P, Lyons G, Kovacevic Z, Mason R, Dixon K, Chan-Ling T, Hawkins C, Sunde M, Lovejoy D, Owens T, Rendina L, Jansson P, Dos Remedios C, Charles (nee Slaviero) K, Lane D, Witting P, Dong Q, Ammit A, Groundwater P, Assinder S, Bao B, Byrne S, Zhou F, Buckland M, Grewal T, Huq F, Lai D, Codd R, Zhang D, Fu D, de Graaf S, Huang M, Payne R, Slobedman B, Barrs V, Ho J, Williamson P, Murphy C; DVC Research/Equipment Grant.
  • Development and operational support for the Australasian Lung cancer Trials Group (ALTG) through the NHMRC Clinical Trial Centre: A NSW-led initiative; Pavlakis N, Boyer M, Stockler M, Dhillon H, Links M, Brown C, Lewis C, Stubbin I; Cancer Institute New South Wales/Cooperative Clinical Trial (CCT) Grants.

2012

  • GeneAtlas Personal Microarray System; Richardson D, Scolyer R, Stocker R, Weninger W, Black J, Allen D, Murray M, Mason R, Twigg S, King N, Horvath L, Lovicu F, Lee C, Halliday G, Lovejoy D, Joshua D, Sharland A, Roufogalis B, Hambly B, Morris B, Bao B, Bishop A, Hibbs D, Lane D, Zhou F, Hanrahan J, Dixon K, Rendina L, Byrne M, Naylor M, Cole N, Jansson P, Dong Q, Codd R, Payne R, Assinder S, Chadban S, Fraser S, McLennan S, Suryo Rahmanto A, Lai D, Yu Y, Ju Y, Buckland M, Kovacevic Z, Saletta F, Zreiqat H, Kalinowski D, Groundwater P, Simes R, Zhang D, Boyer M, Murphy C; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2011

  • NITRO: A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer; Davidson A, Millward M, Boyer M, Millward M, Fong K, McLachlan S, Singhal N, Stockler M; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2010

  • GenomeLab GeXP Genetic Analysis System for the Multi-Disciplinary Sydney Cancer Gene Expression Facility; Richardson D, Halliday G, Scolyer R, Clarke S, Lee C, Reichardt J, Clarke C, Murray M, Boyer M, Kefford R; Cancer Institute New South Wales/Equipment Grant.

2009

  • The impact of physical activity on quality of life in thoracic cancer patients; Vardy J, Dhillon H, Van Der Ploeg H, Clarke S, Boyer M, Bauman A; Lance Armstrong Foundation/Young Investigator Grant.
  • Preferences for adjuvant chemotherapy in early non-small-cell lung cancer: What makes it worthwhile to patients and their doctors?; McLachlan S, Duric V, Stockler M, Nowak A, Wright G, Boyer M, Hudson H; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2008

  • A randomised, phase III trial of adding nitroglycerin to first line chemotherapy in advanced non-small cell lung cancer; Davidson A, Boyer M, Stockler M; Cancer Council New South Wales/Research Project Grants.

2007

  • Pre-clinical development of DpT iron chelators for cancer treatment; Richardson D, Lovejoy D, Boyer M, Horvath L; Cancer Institute New South Wales/Research Grant.

2006

  • The effects of chemotherapy on cognitive function in patients with testicular cancer; Boyer M; Cancer Council New South Wales/Research Project Grants.

2000

  • RCT:economic evaluation of positron emission tomography in management of non small cell lung cancer; Viney R, Fulham M, King M, Boyer M; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Preparing cancer patients for clinical decision making: a randomised trial of preconsultation preparation packages; Tattersall M, Butow P, Boyer M; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Boyer, M. (2003). Pleural and pericardial effusions. In Fisch, Bruera (Eds.), Handbook of Advanced Cancer Care, (pp. 481-487). UK: Cambridge University Press.

Journals

  • Lin, H., Castillo, L., Mahon, K., Chiam, K., B, L., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
  • Yip, P., Cooper, W., Kohonen-Corish, M., Lin, B., McCaughan, B., Boyer, M., Kench, J., Horvath, L. (2014). Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer. Journal of Clinical Pathology, 67(4), 333-340. [More Information]
  • McCaughan, G., Blinman, P., Boyer, M., Stockler, M. (2013). Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancer. Internal Medicine Journal, 43(4), 424-429. [More Information]
  • Spina, R., Chu, S., Chatfield, M., Chen, J., Tin, M., Boyer, M. (2013). Outcomes of Chemoradiation for Patients with Locally Advanced Non-Small-Cell Lung Cancer. Internal Medicine Journal, 43(7), 790-797. [More Information]
  • Yip, P., Yu, B., Cooper, W., Selinger, C., Ng, C., Kennedy, C., Kohonen-Corish, M., McCaughan, B., Trent, R., Boyer, M., Kench, J., Horvath, L., O'Toole, S. (2013). Patterns of DNA mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma. Journal of Thoracic Oncology, 8(4), 408-414. [More Information]
  • Selinger, C., Rogers, T., Russell, P., O'Toole, S., Yip, P., Wright, G., Wainer, Z., Horvath, L., Boyer, M., McCaughan, B., et al (2013). Testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology, 26(12), 1545-1553. [More Information]
  • Kim, G., Mahoney, M., Szydlo, D., Mok, T., Marshke, R., Holen, K., Picus, J., Boyer, M., Pitot, H., Rubin, J., et al (2012). An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Investigational New Drugs, 30(1), 387-394. [More Information]
  • Sundaresan, P., Hruby, G., Hamilton, A., Hong, A., Boyer, M., Chatfield, M., Thompson, J. (2012). Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma. Clinical Oncology, 24(9), e131-e136. [More Information]
  • Boyer, M., McCaughan, B., Barnes, D., Yip, P. (2012). Diagnosis and treatment of lung cancer: A focus on the GPs role. Medicine Today, 13(2), 30-36.
  • Boyer, M., Horwood, K., Pavlakis, N., de Souza, P., Millward, M., Stein, B., Johnston, M., Abell, F., Rischin, D. (2012). Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. Asia-Pacific Journal of Clinical Oncology, 8(3), 248-254. [More Information]
  • Yeo, W., Chung, H., Chan, S., Wang, L., Lim, R., Picus, J., Boyer, M., Mo, F., Koh, J., Rha, S., et al (2012). Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. Journal of Clinical Oncology, 30(27), 3361-3367. [More Information]
  • Ramalingam, S., Blackhall, F., Krzakowski, M., Barrios, C., Park, K., Bover, I., Heo, D., Rosell, R., Talbot, D., Frank, R., Boyer, M., et al (2012). Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 30(27), 3337-3344. [More Information]
  • Dhillon, H., Van Der Ploeg, H., Bell, M., Boyer, M., Clarke, S., Vardy, J. (2012). The impact of physical activity on fatigue and quality of life in lung cancer patients: A randomised controlled trial protocol. BMC Cancer, 12, 1-9. [More Information]
  • Vansteenkiste, J., Solomon, B., Boyer, M., Wolf, J., Miller, N., Di Scala, L., Pylvaenaeinen, I., Petrovic, K., Dimitrijevic, S., Anrys, B., et al (2011). Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model. Journal of Thoracic Oncology, 6(12), 2120-2129. [More Information]
  • Yan, T., Cao, C., Boyer, M., Tin, M., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2011). Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience. Annals of Thoracic and Cardiovascular Surgery, 17(3), 243-249. [More Information]
  • Cox, K., Goel, S., O'Connell, R., Boyer, M., Beale, P., Simes, R., Stockler, M. (2011). Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin. Internal Medicine Journal, 41(2), 172-178. [More Information]
  • Hirsh, V., Paz-Ares, L., Boyer, M., Rosell, R., Middleton, G., Eberhardt, W., Szczesna, A., Reiterer, P., Saleh, M., Arrieta, O., et al (2011). Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 29(19), 2667-2674. [More Information]
  • Cooper, W., O'Toole, S., Boyer, M., Horvath, L., Mahar, A. (2011). What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology, 43(2), 103-115. [More Information]
  • Kao, S., McCaughan, B., Muljono, A., Boyer, M. (2010). A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed. Journal of Thoracic Oncology, 5(3), 405-406. [More Information]
  • Moore, M., Stockler, M., Lim, R., Mok, T., Millward, M., Boyer, M. (2010). A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. Cancer Chemotherapy and Pharmacology, 66(5), 845-850. [More Information]
  • Grimison, P., Stockler, M., Thomson, D., Olver, I., Harvey, V., Gebski, V., Lewis, C., Levi, J., Boyer, M., Gurney, H., Boland, A., Simes, R., et al (2010). Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. National Cancer Institute. Journal, 102(16), 1253-1262. [More Information]
  • Kao, S., Pavlakis, N., Harvie, R., Vardy, J., Boyer, M., van Zandwijk, N., Clarke, S. (2010). High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clinical Cancer Research, 16(23), 5805-5813. [More Information]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Tattersall, M., Boyer, M., Beale, P., Vardy, J., Pavlakis, N., Larke, L. (2010). Patient-Doctor Communication: Use of Complementary and Alternative Medicine by Adult Patients with Cancer. Journal of the Society for Integrative Oncology, 8(2), 56-64. [More Information]
  • Pezaro, C., Rosenthal, M., Gurney, H., Davis, I., Underhill, C., Boyer, M., Kotasek, D., Soloman, B., Toner, G. (2009). An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. American Journal of Clinical Oncology, 32(4), 338-341. [More Information]
  • Soon, Y., Stockler, M., Askie, L., Boyer, M. (2009). Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. Journal of Clinical Oncology, 27(20), 3277-3283. [More Information]
  • Vardy, J., Dadasovich, R., Beale, P., Boyer, M., Clarke, S. (2009). Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. BMC Cancer, 9(Article number 130), 130-1-130-6. [More Information]
  • Yan, T., Boyer, M., Tin, M., Wong, D., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2009). Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. The Journal of Thoracic and Cardiovascular Surgery, 138(3), 619-624. [More Information]
  • Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., et al (2009). Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research, 69(19), 7696-7703. [More Information]
  • Simonella, L., O’Connell, D., Vinod, S., Delaney, G., Boyer, M., Esmaili, N., Hensley, M., Goldsbury, D., Supramaniam, R., Hui, A., Armstrong, B. (2009). No improvement in lung cancer care: The management of lung cancer in 1996 and 2002 in New South Wales. Internal Medicine Journal, 39, 453-458. [More Information]
  • Yan, T., Boyer, M., Tin, M., Sim, J., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2009). Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma. The Annals of Thoracic Surgery, 87(5), 1552-1556. [More Information]
  • Soon, Y., Stockler, M., Boyer, M. (2009). Reply to A.D. Sasse et al. Journal of Clinical Oncology, 27(35), e254. [More Information]
  • Tattersall, M., Dear, R., Jansen, J., Shepherd, H., Devine, R., Horvath, L., Boyer, M. (2009). Second opinions in oncology: the experiences of patients attending the Sydney Cancer Centre. Medical Journal of Australia, 191(4), 209-212. [More Information]
  • Martin, R., Fulham, M., Shannon, K., Hughes, C., Gao, K., Milross, C., Tin, M., Jackson, M., Clifford, A., Boyer, M., O'Brien, C. (2008). Accuracy of positron emission tomography in the evaluation of patients treated with chemoradiotherapy for mucosal head and neck cancer. Head and Neck, 31(2), 244-250. [More Information]
  • Vinod, S., O'Connell, D., Simonella, L., Delaney, G., Boyer, M., Peters, M., Miller, D., Peters, M., Supramaniam, R., McCawley, L., Armstrong, B. (2008). Gaps in optimal care for lung cancer. Journal of Thoracic Oncology, 3(8), 871-879. [More Information]
  • Kenny, P., King, M., Viney, R., Boyer, M., Pollicino, C., McLean, J., Fulham, M., McCaughan, B. (2008). Quality of life and survival in the 2 years after surgery for non-small-cell lung cancer. Journal of Clinical Oncology, 26(2), 233-241. [More Information]
  • Findlay, M., Storey, D., Gebski, V., Hargreaves, C., Cullingford, G., Boyer, M., Trotter, J., Archer, S., Davidson, A., Johnston, P., Yuen, J., Dhillon, H., et al (2007). A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group study 9601. ANZ Journal of Surgery, 77(4), 247-252.
  • Streit, J., Gao, K., O'Brien, C., Boyer, M., Milross, C. (2007). Hn11p primary chemo-radiotherapy for non-metastatic squamous cell carcinoma of the head and neck. ANZ Journal of Surgery, 77, A39.
  • Yeo, W., Boyer, M., Chung, H., Ong, S., Lim, R., Zee, B., Ma, B., Lam, K., Mo, F., Ng, E., Clarke, S., Beale, P., et al (2007). Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). Cancer Chemotherapy and Pharmacology, 59(3), 295-300. [More Information]
  • Chuah, B., Lim, R., Boyer, M., Ong, A., Wong, S., Kong, H., Millward, M., Clarke, S., Goh, B. (2007). Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncologica, 46(2), 234-238. [More Information]
  • Oates, J., Clark, J., Jane, R., Reeves, N., Gao, K., Jackson, M., Boyer, M., O'Brien, C. (2007). Prospective evaluation of quality of life and nutrition before and after treatment for nasopharyngeal carcinoma. Archives Of Otolaryngology-Head and Neck Surgery, 133(6), 533-540. [More Information]
  • Soo, R., Wang, L., Tham, L., Yong, W., Boyer, M., Lee, H., Lim, H., Millward, M., Liang, S., Beale, P., et al (2006). A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Annals of Oncology, 17(7), 1128-1133.
  • Stockler, M., Tattersall, M., Boyer, M., Clarke, S., Beale, P., Simes, R. (2006). Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. British Journal of Cancer, 94(2), 208-212. [More Information]
  • Hsin, K., Boyer, M., Ducreux, M., Liu, M., Soo, R., Yeo, W., Williams, K., Johri, A. (2006). Efficacy of patupilone in advanced local or metastatic gastric cancer: A phase IIa trial. Journal of Clinical Oncology, 24(18S), 195 (Abstract 4069)-195.
  • Abratt, R., Lee, J., Han, J., Tsai, C., Boyer, M., Mok, T., Kim, S., Lee, J., Brnabic, A., Reece, W. (2006). Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer. Journal of Thoracic Oncology, 1(2), 135-140.
  • Charles (nee Slaviero), K., Rivory, L., Stockler, M., Beale, P., Beith, J., Boyer, M., Clarke, S. (2006). Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical Pharmacokinetics, 45(6), 611-622. [More Information]
  • Cebon, J., Hargreaves, C., Stockler, M., Boyer, M., Nowak, A., Dhillon, H., Gebski, V., Dickman, B., Findlay, M., Poon, A., et al (2006). Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. British Journal of Cancer, 95(7), 853-861. [More Information]
  • Clarke, S., Boyer, M., Millward, M., Underhill, C., Moylan, E., Yip, D., White, S., Childs, A., Beale, P., Latz, J., et al (2005). A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer, 49(3), 401-412. [More Information]
  • van Meerbeeck, J., Boyer, M. (2005). Consensus report: pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma. Lung Cancer, 49(Supplement 1), S123-S127. [More Information]
  • Sharma, R., Boyer, M., Clarke, S., Millward, M. (2005). Gefitinib in advanced non-small cell lung cancer. Internal Medicine Journal, 35(2), 77. [More Information]
  • Underhill, C., Hui, R., Links, M., Hawson, G., Chern, B., Yip, D., Blackwell, T., Crombie, C., Boyer, M. (2005). Phase II study of docetaxel and celecoxib as first or second line therapy in patients with advanced NSCLC. Lung Cancer, 49(Sup.2), S272-S273.
  • Joshua, A., Boyer, M., Subramanian, R., Clarke, S. (2005). Smoking reduction does work: resulting alterations in the incidence and histological subtypes of lung cancer in New South Wales in the last 20 years. Respirology, 10(2), 233-238. [More Information]
  • Joshua, A., Nordman, I., Venkataswaran, R., Clarke, S., Stockler, M., Boyer, M. (2005). Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Internal Medicine Journal, 35(8), 468-472. [More Information]
  • Cox, K., O'Connell, R., Stockler, M., Boyer, M., Beale, P., Simes, R. (2004). A randomized crossover trial of giving high-dose cisplatin with or without an overnight stay in hospital: Patients' preferences, quality of life, safety and resource use. Journal of Clinical Oncology, 22(14S), 547S-547S.
  • Butow, P., Boyer, M., Tattersall, M., Pendlebury, S., Jackson, M., Fung, C. (2004). Cancer Consultation Preparation Package: Changing Patients But Not Physicians Is Not Enough. Journal of Clinical Oncology, 22(21), 4401-4409.
  • Vardy, J., Engelhardt, K., Cox, K., Jacquet, J., McDade, A., Boyer, M., Beale, P., Clarke, S., Stockler, M., Loneragan, R., Waugh, R., Clarke, S. (2004). Long-Term Outcome Of Radiological-Guided Insertion Of Implanted Central Venous Access Port Devices (Cvapd) For The Delivery Of Chemotherapy In Cancer Patients: Institutional Experience And Review Of The Literature. British Journal of Cancer, 91(6), 1045-1049.
  • Joshua, A., Stockler, M., Boyer, M. (2004). Prolonged survival after the diagnosis of metastatic hepatic epitheliod haemangioendothelioma. Internal Medicine Journal, 34(1-2), 70-71.
  • Zhang, M., Boyer, M., Rivory, L., Hong, A., Clarke, S., Stevens, G., Fife, K. (2004). Radiosensitization Of Vinorelbine And Gemcitabine In Nci-H460 Non-Small-Cell Lung Cancer Cells. International Journal of Radiation: Oncology - Biology - Physics, 58(2), 353-360. [More Information]
  • Viney, R., Boyer, M., King, M., Kenny, P., Pollicino, C., McLean, J., McCaughan, B., Fulham, M. (2004). Randomized Controlled Trial Of The Role Of Positron Emission Tomography In The Management Of Stage I And Ii Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 22(12), 2357-2362.
  • Millward, M., Boyer, M., Lehnert, M., Clarke, S., Rischin, D., Goh, B., Wong, J., McNeil, E., Bishop, J. (2003). Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Annals of Oncology, 14(3), 449-454.
  • Abol-Enein, H., Bassi, P., Boyer, M., Coppin, C., Cortesi, E., Hall, R., Horwich, A., Malmström, P., Martinez-Piñeiro, J., Sengelov, L., et al (2003). Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. The Lancet, 361(9373), 1927-1934.
  • Vogelzang, N., Rusthoven, J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al (2003). Phase III study of premetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology, 21(14), 2636-2644.
  • Boyer, M., Stockler, M., Rosenthal, M., Eisinger, D., Goad, J., Webb, D. (2002). Adjuvant mitoxantrone chemotherapy for men at high risk of relapse following radical prostatectomy: a pilot study. UroOncology, 2(1), 15-17.
  • Boyer, M., Clarke, S. (2002). Current management of lung cancer. Current Therapeutics: Australia's journal of disease management and drug treatment, 43/44(12/1), 49-54.
  • Cassidy, J., Twelves, C., Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., et al (2002). First-line oral capecitabine therapy in metastatic colorectal cancer: a favourable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology, 13, 566-575.
  • Boyer, M., Rivory, L., Clarke, S. (2002). Pemetrexed: single-agent and combination phase 1 study overview. Seminars in Oncology, 29(6 - Supplement 18), 18-23.
  • Clarke, S., Abratt, R., Goedhals, L., Boyer, M., Millward, M., Ackland, S. (2002). Phase II trial of pemetrexed disodium (ALIMTA[R], LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Annals of Oncology, 13(5), 737-741.
  • Horvath, L., McCaughan, B., Stockler, M., Boyer, M. (2002). Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours. Internal Medicine Journal, 32(3), 79-83.
  • Toner, G., Stockler, M., Boyer, M., Jones, M., Thomson, D., Harvey, V., Olver, I., Dhillon, H., McMullen, A., Gebski, V., Levi, J., Simes, R. (2001). Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. The Lancet, 357(9528), 739-745.
  • Rivory, L., Clarke, S., Boyer, M., Bishop, J. (2001). Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 765, 135-140.
  • Rischin, D., Boyer, M., Smith, J., Millward, M., Michael, M., Bishop, J., Zalcberg, J., Davison, J., Emmett, E., McClure, B. (2000). A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Annals of Oncology, 11, 421-426.
  • Rischin, D., Smith, J., Millward, M., Lewis, C., Richardson, G., Boyer, M., Toner, G., Gurney, H., McKendrick, J. (2000). A phase II trial of paclitaxel and epirubicin in advanced breast cancer. British Journal of Cancer, 83(4), 438-442.
  • Dowsett, S., Saul, J., Butow, P., Dunn, S., Boyer, M., Findlow, R., Dunsmore, J. (2000). Communication styles in the cancer consultation: preferences for a patient-centred approach. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 9, 147-156.
  • Rivory, L., Charles (nee Slaviero), K., Seale, J., Hoskins, J., Boyer, M., Beale, P., Millward, M., Bishop, J., Clarke, S. (2000). Optimizing the erythromycin breath test for use in cancer patients. Clinical Cancer Research, 6, 3480-3485.
  • Klasterksy, J., Paesmans, M., Rubenstein, E., Boyer, M., Elting, L., Feld, R., Gallagher, J., Herrstedt, J., Rapoport, B., et, A. (2000). The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of Clinical Oncology, 18, 3038-3051.
  • von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L., Clark, P., Talbot, D., Rey, A., Butler, T., Hirsh, V., et al (2000). Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Journal of Clinical Oncology, 18, 1351-1359.

Conferences

  • Miller, D., Boyer, M., Supramaniam, R., Armstrong, B., Simonella, L., O'Connell, D., Vinod, S., McCawley, L., Delaney, G. (2007). Patterns of lung cancer care in NSW, Australia. 12th World Conference on Lung Cancer, United Kingdom: Wiley-Blackwell Publishing.
  • Clarke, S., Boyer, M., Stockler, M., Venkatawaran, R., Nordman, I., Joshua, A. (2005). Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC). 2005 ASCO Annual Meeting, NY, USA: American Society of Clinical Oncology.
  • Cullingford, G., Findlay, M., Storey, D., Boyer, M., Trotter, J., Archer, S., Davidson, A., Johnston, P., Gebski, V., Dhillon, H. (2002). A phase II feasibility study of pre-operative and post-operative chemotherapy (epirubicin, cisplatin and 4FU (ECF)) in patients with advanced but operable gastric cancer: and Australasian Gastro-Intestinal Trials Group (AGITG) study (AG9601). 38th Annual Meeting of ASCO.

2014

  • Lin, H., Castillo, L., Mahon, K., Chiam, K., B, L., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
  • Yip, P., Cooper, W., Kohonen-Corish, M., Lin, B., McCaughan, B., Boyer, M., Kench, J., Horvath, L. (2014). Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer. Journal of Clinical Pathology, 67(4), 333-340. [More Information]

2013

  • McCaughan, G., Blinman, P., Boyer, M., Stockler, M. (2013). Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancer. Internal Medicine Journal, 43(4), 424-429. [More Information]
  • Spina, R., Chu, S., Chatfield, M., Chen, J., Tin, M., Boyer, M. (2013). Outcomes of Chemoradiation for Patients with Locally Advanced Non-Small-Cell Lung Cancer. Internal Medicine Journal, 43(7), 790-797. [More Information]
  • Yip, P., Yu, B., Cooper, W., Selinger, C., Ng, C., Kennedy, C., Kohonen-Corish, M., McCaughan, B., Trent, R., Boyer, M., Kench, J., Horvath, L., O'Toole, S. (2013). Patterns of DNA mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma. Journal of Thoracic Oncology, 8(4), 408-414. [More Information]
  • Selinger, C., Rogers, T., Russell, P., O'Toole, S., Yip, P., Wright, G., Wainer, Z., Horvath, L., Boyer, M., McCaughan, B., et al (2013). Testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology, 26(12), 1545-1553. [More Information]

2012

  • Kim, G., Mahoney, M., Szydlo, D., Mok, T., Marshke, R., Holen, K., Picus, J., Boyer, M., Pitot, H., Rubin, J., et al (2012). An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Investigational New Drugs, 30(1), 387-394. [More Information]
  • Sundaresan, P., Hruby, G., Hamilton, A., Hong, A., Boyer, M., Chatfield, M., Thompson, J. (2012). Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma. Clinical Oncology, 24(9), e131-e136. [More Information]
  • Boyer, M., McCaughan, B., Barnes, D., Yip, P. (2012). Diagnosis and treatment of lung cancer: A focus on the GPs role. Medicine Today, 13(2), 30-36.
  • Boyer, M., Horwood, K., Pavlakis, N., de Souza, P., Millward, M., Stein, B., Johnston, M., Abell, F., Rischin, D. (2012). Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. Asia-Pacific Journal of Clinical Oncology, 8(3), 248-254. [More Information]
  • Yeo, W., Chung, H., Chan, S., Wang, L., Lim, R., Picus, J., Boyer, M., Mo, F., Koh, J., Rha, S., et al (2012). Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. Journal of Clinical Oncology, 30(27), 3361-3367. [More Information]
  • Ramalingam, S., Blackhall, F., Krzakowski, M., Barrios, C., Park, K., Bover, I., Heo, D., Rosell, R., Talbot, D., Frank, R., Boyer, M., et al (2012). Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 30(27), 3337-3344. [More Information]
  • Dhillon, H., Van Der Ploeg, H., Bell, M., Boyer, M., Clarke, S., Vardy, J. (2012). The impact of physical activity on fatigue and quality of life in lung cancer patients: A randomised controlled trial protocol. BMC Cancer, 12, 1-9. [More Information]

2011

  • Vansteenkiste, J., Solomon, B., Boyer, M., Wolf, J., Miller, N., Di Scala, L., Pylvaenaeinen, I., Petrovic, K., Dimitrijevic, S., Anrys, B., et al (2011). Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model. Journal of Thoracic Oncology, 6(12), 2120-2129. [More Information]
  • Yan, T., Cao, C., Boyer, M., Tin, M., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2011). Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience. Annals of Thoracic and Cardiovascular Surgery, 17(3), 243-249. [More Information]
  • Cox, K., Goel, S., O'Connell, R., Boyer, M., Beale, P., Simes, R., Stockler, M. (2011). Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin. Internal Medicine Journal, 41(2), 172-178. [More Information]
  • Hirsh, V., Paz-Ares, L., Boyer, M., Rosell, R., Middleton, G., Eberhardt, W., Szczesna, A., Reiterer, P., Saleh, M., Arrieta, O., et al (2011). Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 29(19), 2667-2674. [More Information]
  • Cooper, W., O'Toole, S., Boyer, M., Horvath, L., Mahar, A. (2011). What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology, 43(2), 103-115. [More Information]

2010

  • Kao, S., McCaughan, B., Muljono, A., Boyer, M. (2010). A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed. Journal of Thoracic Oncology, 5(3), 405-406. [More Information]
  • Moore, M., Stockler, M., Lim, R., Mok, T., Millward, M., Boyer, M. (2010). A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. Cancer Chemotherapy and Pharmacology, 66(5), 845-850. [More Information]
  • Grimison, P., Stockler, M., Thomson, D., Olver, I., Harvey, V., Gebski, V., Lewis, C., Levi, J., Boyer, M., Gurney, H., Boland, A., Simes, R., et al (2010). Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. National Cancer Institute. Journal, 102(16), 1253-1262. [More Information]
  • Kao, S., Pavlakis, N., Harvie, R., Vardy, J., Boyer, M., van Zandwijk, N., Clarke, S. (2010). High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clinical Cancer Research, 16(23), 5805-5813. [More Information]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Tattersall, M., Boyer, M., Beale, P., Vardy, J., Pavlakis, N., Larke, L. (2010). Patient-Doctor Communication: Use of Complementary and Alternative Medicine by Adult Patients with Cancer. Journal of the Society for Integrative Oncology, 8(2), 56-64. [More Information]

2009

  • Pezaro, C., Rosenthal, M., Gurney, H., Davis, I., Underhill, C., Boyer, M., Kotasek, D., Soloman, B., Toner, G. (2009). An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. American Journal of Clinical Oncology, 32(4), 338-341. [More Information]
  • Soon, Y., Stockler, M., Askie, L., Boyer, M. (2009). Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. Journal of Clinical Oncology, 27(20), 3277-3283. [More Information]
  • Vardy, J., Dadasovich, R., Beale, P., Boyer, M., Clarke, S. (2009). Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. BMC Cancer, 9(Article number 130), 130-1-130-6. [More Information]
  • Yan, T., Boyer, M., Tin, M., Wong, D., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2009). Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. The Journal of Thoracic and Cardiovascular Surgery, 138(3), 619-624. [More Information]
  • Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., et al (2009). Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research, 69(19), 7696-7703. [More Information]
  • Simonella, L., O’Connell, D., Vinod, S., Delaney, G., Boyer, M., Esmaili, N., Hensley, M., Goldsbury, D., Supramaniam, R., Hui, A., Armstrong, B. (2009). No improvement in lung cancer care: The management of lung cancer in 1996 and 2002 in New South Wales. Internal Medicine Journal, 39, 453-458. [More Information]
  • Yan, T., Boyer, M., Tin, M., Sim, J., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2009). Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma. The Annals of Thoracic Surgery, 87(5), 1552-1556. [More Information]
  • Soon, Y., Stockler, M., Boyer, M. (2009). Reply to A.D. Sasse et al. Journal of Clinical Oncology, 27(35), e254. [More Information]
  • Tattersall, M., Dear, R., Jansen, J., Shepherd, H., Devine, R., Horvath, L., Boyer, M. (2009). Second opinions in oncology: the experiences of patients attending the Sydney Cancer Centre. Medical Journal of Australia, 191(4), 209-212. [More Information]

2008

  • Martin, R., Fulham, M., Shannon, K., Hughes, C., Gao, K., Milross, C., Tin, M., Jackson, M., Clifford, A., Boyer, M., O'Brien, C. (2008). Accuracy of positron emission tomography in the evaluation of patients treated with chemoradiotherapy for mucosal head and neck cancer. Head and Neck, 31(2), 244-250. [More Information]
  • Vinod, S., O'Connell, D., Simonella, L., Delaney, G., Boyer, M., Peters, M., Miller, D., Peters, M., Supramaniam, R., McCawley, L., Armstrong, B. (2008). Gaps in optimal care for lung cancer. Journal of Thoracic Oncology, 3(8), 871-879. [More Information]
  • Kenny, P., King, M., Viney, R., Boyer, M., Pollicino, C., McLean, J., Fulham, M., McCaughan, B. (2008). Quality of life and survival in the 2 years after surgery for non-small-cell lung cancer. Journal of Clinical Oncology, 26(2), 233-241. [More Information]

2007

  • Findlay, M., Storey, D., Gebski, V., Hargreaves, C., Cullingford, G., Boyer, M., Trotter, J., Archer, S., Davidson, A., Johnston, P., Yuen, J., Dhillon, H., et al (2007). A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group study 9601. ANZ Journal of Surgery, 77(4), 247-252.
  • Streit, J., Gao, K., O'Brien, C., Boyer, M., Milross, C. (2007). Hn11p primary chemo-radiotherapy for non-metastatic squamous cell carcinoma of the head and neck. ANZ Journal of Surgery, 77, A39.
  • Yeo, W., Boyer, M., Chung, H., Ong, S., Lim, R., Zee, B., Ma, B., Lam, K., Mo, F., Ng, E., Clarke, S., Beale, P., et al (2007). Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). Cancer Chemotherapy and Pharmacology, 59(3), 295-300. [More Information]
  • Chuah, B., Lim, R., Boyer, M., Ong, A., Wong, S., Kong, H., Millward, M., Clarke, S., Goh, B. (2007). Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncologica, 46(2), 234-238. [More Information]
  • Miller, D., Boyer, M., Supramaniam, R., Armstrong, B., Simonella, L., O'Connell, D., Vinod, S., McCawley, L., Delaney, G. (2007). Patterns of lung cancer care in NSW, Australia. 12th World Conference on Lung Cancer, United Kingdom: Wiley-Blackwell Publishing.
  • Oates, J., Clark, J., Jane, R., Reeves, N., Gao, K., Jackson, M., Boyer, M., O'Brien, C. (2007). Prospective evaluation of quality of life and nutrition before and after treatment for nasopharyngeal carcinoma. Archives Of Otolaryngology-Head and Neck Surgery, 133(6), 533-540. [More Information]

2006

  • Soo, R., Wang, L., Tham, L., Yong, W., Boyer, M., Lee, H., Lim, H., Millward, M., Liang, S., Beale, P., et al (2006). A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Annals of Oncology, 17(7), 1128-1133.
  • Stockler, M., Tattersall, M., Boyer, M., Clarke, S., Beale, P., Simes, R. (2006). Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. British Journal of Cancer, 94(2), 208-212. [More Information]
  • Hsin, K., Boyer, M., Ducreux, M., Liu, M., Soo, R., Yeo, W., Williams, K., Johri, A. (2006). Efficacy of patupilone in advanced local or metastatic gastric cancer: A phase IIa trial. Journal of Clinical Oncology, 24(18S), 195 (Abstract 4069)-195.
  • Abratt, R., Lee, J., Han, J., Tsai, C., Boyer, M., Mok, T., Kim, S., Lee, J., Brnabic, A., Reece, W. (2006). Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer. Journal of Thoracic Oncology, 1(2), 135-140.
  • Charles (nee Slaviero), K., Rivory, L., Stockler, M., Beale, P., Beith, J., Boyer, M., Clarke, S. (2006). Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical Pharmacokinetics, 45(6), 611-622. [More Information]
  • Cebon, J., Hargreaves, C., Stockler, M., Boyer, M., Nowak, A., Dhillon, H., Gebski, V., Dickman, B., Findlay, M., Poon, A., et al (2006). Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. British Journal of Cancer, 95(7), 853-861. [More Information]

2005

  • Clarke, S., Boyer, M., Millward, M., Underhill, C., Moylan, E., Yip, D., White, S., Childs, A., Beale, P., Latz, J., et al (2005). A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer, 49(3), 401-412. [More Information]
  • van Meerbeeck, J., Boyer, M. (2005). Consensus report: pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma. Lung Cancer, 49(Supplement 1), S123-S127. [More Information]
  • Sharma, R., Boyer, M., Clarke, S., Millward, M. (2005). Gefitinib in advanced non-small cell lung cancer. Internal Medicine Journal, 35(2), 77. [More Information]
  • Underhill, C., Hui, R., Links, M., Hawson, G., Chern, B., Yip, D., Blackwell, T., Crombie, C., Boyer, M. (2005). Phase II study of docetaxel and celecoxib as first or second line therapy in patients with advanced NSCLC. Lung Cancer, 49(Sup.2), S272-S273.
  • Joshua, A., Boyer, M., Subramanian, R., Clarke, S. (2005). Smoking reduction does work: resulting alterations in the incidence and histological subtypes of lung cancer in New South Wales in the last 20 years. Respirology, 10(2), 233-238. [More Information]
  • Clarke, S., Boyer, M., Stockler, M., Venkatawaran, R., Nordman, I., Joshua, A. (2005). Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC). 2005 ASCO Annual Meeting, NY, USA: American Society of Clinical Oncology.
  • Joshua, A., Nordman, I., Venkataswaran, R., Clarke, S., Stockler, M., Boyer, M. (2005). Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Internal Medicine Journal, 35(8), 468-472. [More Information]

2004

  • Cox, K., O'Connell, R., Stockler, M., Boyer, M., Beale, P., Simes, R. (2004). A randomized crossover trial of giving high-dose cisplatin with or without an overnight stay in hospital: Patients' preferences, quality of life, safety and resource use. Journal of Clinical Oncology, 22(14S), 547S-547S.
  • Butow, P., Boyer, M., Tattersall, M., Pendlebury, S., Jackson, M., Fung, C. (2004). Cancer Consultation Preparation Package: Changing Patients But Not Physicians Is Not Enough. Journal of Clinical Oncology, 22(21), 4401-4409.
  • Vardy, J., Engelhardt, K., Cox, K., Jacquet, J., McDade, A., Boyer, M., Beale, P., Clarke, S., Stockler, M., Loneragan, R., Waugh, R., Clarke, S. (2004). Long-Term Outcome Of Radiological-Guided Insertion Of Implanted Central Venous Access Port Devices (Cvapd) For The Delivery Of Chemotherapy In Cancer Patients: Institutional Experience And Review Of The Literature. British Journal of Cancer, 91(6), 1045-1049.
  • Joshua, A., Stockler, M., Boyer, M. (2004). Prolonged survival after the diagnosis of metastatic hepatic epitheliod haemangioendothelioma. Internal Medicine Journal, 34(1-2), 70-71.
  • Zhang, M., Boyer, M., Rivory, L., Hong, A., Clarke, S., Stevens, G., Fife, K. (2004). Radiosensitization Of Vinorelbine And Gemcitabine In Nci-H460 Non-Small-Cell Lung Cancer Cells. International Journal of Radiation: Oncology - Biology - Physics, 58(2), 353-360. [More Information]
  • Viney, R., Boyer, M., King, M., Kenny, P., Pollicino, C., McLean, J., McCaughan, B., Fulham, M. (2004). Randomized Controlled Trial Of The Role Of Positron Emission Tomography In The Management Of Stage I And Ii Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 22(12), 2357-2362.

2003

  • Millward, M., Boyer, M., Lehnert, M., Clarke, S., Rischin, D., Goh, B., Wong, J., McNeil, E., Bishop, J. (2003). Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Annals of Oncology, 14(3), 449-454.
  • Abol-Enein, H., Bassi, P., Boyer, M., Coppin, C., Cortesi, E., Hall, R., Horwich, A., Malmström, P., Martinez-Piñeiro, J., Sengelov, L., et al (2003). Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. The Lancet, 361(9373), 1927-1934.
  • Vogelzang, N., Rusthoven, J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al (2003). Phase III study of premetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology, 21(14), 2636-2644.
  • Boyer, M. (2003). Pleural and pericardial effusions. In Fisch, Bruera (Eds.), Handbook of Advanced Cancer Care, (pp. 481-487). UK: Cambridge University Press.

2002

  • Cullingford, G., Findlay, M., Storey, D., Boyer, M., Trotter, J., Archer, S., Davidson, A., Johnston, P., Gebski, V., Dhillon, H. (2002). A phase II feasibility study of pre-operative and post-operative chemotherapy (epirubicin, cisplatin and 4FU (ECF)) in patients with advanced but operable gastric cancer: and Australasian Gastro-Intestinal Trials Group (AGITG) study (AG9601). 38th Annual Meeting of ASCO.
  • Boyer, M., Stockler, M., Rosenthal, M., Eisinger, D., Goad, J., Webb, D. (2002). Adjuvant mitoxantrone chemotherapy for men at high risk of relapse following radical prostatectomy: a pilot study. UroOncology, 2(1), 15-17.
  • Boyer, M., Clarke, S. (2002). Current management of lung cancer. Current Therapeutics: Australia's journal of disease management and drug treatment, 43/44(12/1), 49-54.
  • Cassidy, J., Twelves, C., Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., et al (2002). First-line oral capecitabine therapy in metastatic colorectal cancer: a favourable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology, 13, 566-575.
  • Boyer, M., Rivory, L., Clarke, S. (2002). Pemetrexed: single-agent and combination phase 1 study overview. Seminars in Oncology, 29(6 - Supplement 18), 18-23.
  • Clarke, S., Abratt, R., Goedhals, L., Boyer, M., Millward, M., Ackland, S. (2002). Phase II trial of pemetrexed disodium (ALIMTA[R], LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Annals of Oncology, 13(5), 737-741.
  • Horvath, L., McCaughan, B., Stockler, M., Boyer, M. (2002). Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours. Internal Medicine Journal, 32(3), 79-83.

2001

  • Toner, G., Stockler, M., Boyer, M., Jones, M., Thomson, D., Harvey, V., Olver, I., Dhillon, H., McMullen, A., Gebski, V., Levi, J., Simes, R. (2001). Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. The Lancet, 357(9528), 739-745.
  • Rivory, L., Clarke, S., Boyer, M., Bishop, J. (2001). Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 765, 135-140.

2000

  • Rischin, D., Boyer, M., Smith, J., Millward, M., Michael, M., Bishop, J., Zalcberg, J., Davison, J., Emmett, E., McClure, B. (2000). A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Annals of Oncology, 11, 421-426.
  • Rischin, D., Smith, J., Millward, M., Lewis, C., Richardson, G., Boyer, M., Toner, G., Gurney, H., McKendrick, J. (2000). A phase II trial of paclitaxel and epirubicin in advanced breast cancer. British Journal of Cancer, 83(4), 438-442.
  • Dowsett, S., Saul, J., Butow, P., Dunn, S., Boyer, M., Findlow, R., Dunsmore, J. (2000). Communication styles in the cancer consultation: preferences for a patient-centred approach. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 9, 147-156.
  • Rivory, L., Charles (nee Slaviero), K., Seale, J., Hoskins, J., Boyer, M., Beale, P., Millward, M., Bishop, J., Clarke, S. (2000). Optimizing the erythromycin breath test for use in cancer patients. Clinical Cancer Research, 6, 3480-3485.
  • Klasterksy, J., Paesmans, M., Rubenstein, E., Boyer, M., Elting, L., Feld, R., Gallagher, J., Herrstedt, J., Rapoport, B., et, A. (2000). The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of Clinical Oncology, 18, 3038-3051.
  • von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L., Clark, P., Talbot, D., Rey, A., Butler, T., Hirsh, V., et al (2000). Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Journal of Clinical Oncology, 18, 1351-1359.

To update your profile click here. For support on your academic profile contact .